Kory James Wentworth - Sep 1, 2022 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role: Chief Financial Officer
Signature: /s/ Jared Cohen, as Attorneyin-in-Fact
Stock symbol: TRDA
Transactions as of: Sep 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 9/6/2022, 04:34 PM
Previous filing: Aug 26, 2022
Next filing: Nov 18, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRDA	Common Stock	Award	$0	+5.5K	+50.09%	$0.00	16.5K	Sep 1, 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

Content

Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.